Fig. 1From: Migalastat improves diarrhea in patients with Fabry disease: clinical-biomarker correlations from the phase 3 FACETS trialPatients experiencing a minimal clinically important difference in GSRS-D scores after 6 months of treatment. a Improvement of 0.33. b Forest plot showing the effect size of migalastat treatment vs placebo. c Sensitivity analysis: improvement of 0.66Back to article page